Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript

What happened: Acrivon Therapeutics (ACRV) hosted a webcast with a key opinion leader panel to discuss its recently announced acquisition of two immunology and inflammation assets: ACR-525, an oral JAK1 inhibitor formerly known as AQ280, and a PKC theta inhibitor preclinical program. Why it matters: Management said the deal executes on its stated strategy, citing the suitability of its AI-driven AP3 platform for immunology and inflammation and calling ACR-525 a highly differentiated oral JAK1 inhibitor.

Acrivon Therapeutics (ACRV) hosted a webcast with a key opinion leader panel to discuss its recently announced acquisition of two immunology and inflammation assets: ACR-525, an oral JAK1 inhibitor formerly known as AQ280, and a PKC theta inhibitor preclinical program.

Management said the deal executes on its stated strategy, citing the suitability of its AI-driven AP3 platform for immunology and inflammation and calling ACR-525 a highly differentiated oral JAK1 inhibitor.